ORAGENICS INC
For the period ended Jun 30, 2025. Filed Aug 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 8, 2025
OGEN$0.34-3.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| For the Six Months Ended June 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(4,489,028) | $(4,755,923) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Amortization of debt discount and closing costs | 771,437 | - |
| Stock-based compensation expense | 24,485 | 127,564 |
| Stock-based compensation recapture expense | (86,617) | - |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 441,707 | 111,939 |
| Operating lease right of use assets | - | 9,811 |
| Accounts payable and accrued expenses | (88,444) | (92,358) |
| Change in operating lease liabilities | - | (9,811) |
| Net cash used in operating activities | (3,426,460) | (4,608,778) |
| Cash flows from financing activities: | ||
| Borrowings on short-term notes payable | 2,228,563 | - |
| Payments on short-term notes payable | (328,528) | (312,703) |
| Net proceeds from issuance of common stock | 2,635,330 | 2,786,601 |
| Net cash provided by financing activities | 4,535,365 | 2,473,898 |
| Net decrease in cash and cash equivalents | 1,108,905 | (2,134,880) |
| Cash and cash equivalents at beginning of period | 864,840 | 3,483,501 |
| Cash and cash equivalents at end of period | $1,973,745 | $1,348,621 |
| Supplemental disclosure of cash flow information: | ||
| Interest paid | $7,860 | $8,888 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.